Nearly Half of America’s In-Licensed Drugs Now Start in China, a Dependency Treasury Just Decided Not to Break
Treasury will allow most US pharma licensing deals with China, restricting only pathogen work. The reason is commercial: nearly half of US in-licensed drugs now originate in China.


